AbbVie (ABBV) Non-Current Debt (2012 - 2026)

AbbVie (ABBV) has 15 years of Non-Current Debt data on file, last reported at $64.5 billion in Q1 2026.

• Quarterly Non-Current Debt changed 0.01% year-over-year to $64.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.5 billion (changed 0.01% YoY) and the FY2025 annual result came in at $58.9 billion, down 2.32% from the prior year.
• Non-Current Debt improved to $64.5 billion in Q1 2026 per ABBV's latest filing, from $58.9 billion in the prior quarter.
• Across five years, Non-Current Debt topped out at $64.5 billion in Q1 2026 and bottomed at $52.2 billion in Q4 2023.
• The 5-year median for Non-Current Debt is $60.3 billion (2024), against an average of $60.1 billion.
• The widest annual swing landed in 2022, when Non-Current Debt retreated 18.43%; it then gained 15.61% in 2024.
• Tracing ABBV's Non-Current Debt over 5 years: stood at $59.1 billion in 2022, then slipped by 11.74% to $52.2 billion in 2023, then increased by 15.61% to $60.3 billion in 2024, then retreated by 2.32% to $58.9 billion in 2025, then grew by 9.49% to $64.5 billion in 2026.
• Per Business Quant, the three latest ABBV Non-Current Debt figures stand at $64.5 billion (Q1 2026), $58.9 billion (Q4 2025), and $63.0 billion (Q3 2025).

Peer Comparison